In the event of the onset of type I diabetes (TID) the circulating autoantibodies against the beta-cell of the pancreas are attacked by macrophages and autoreactive lymphocytes under the influence of different cytokines. Eventually, beta-cells are destroyed through apoptosis, or natural killer cells, or a scavenger process. Cyclooxygenase (COX)-2 is constitutively expressed in beta-cells, the possible role in insulin secretion and insulitis has been suggested. However, COX-2 with lymphocytes and other infiltrated leukocytes on diabetogenesis remains largely elusive. We injected diabetic lymphocytes of non-obese diabetic (NOD) mice to NOD/SCID mice for adoptive transfer. The diabetogenesis of adoptive transferred NOD/SCm mice was tested with supplements of COX-2 inhibitor or the substrate, arachidonic acid, in the diets under placebo control. The tissues of intestine and pancreas of BALB/c, NOD and NOD/SCID mice were immunohistochemically analyzed. COX-2 and insulin were revealed in the vesicles of beta-cells in intact islets of BALB/c mice. The lymphocyte tracking of the transferred lymphocytes and COX-2 expression in beta-cells and emerged leukocytes showed that celecoxib, or the substrate did not change the pattern of lymphocyte accumulation in the pancreas compared to placebo, even though the development of severe diabetes was slightly different. COX-2 was only expressed in macrophages, rather than infiltrated lymphocytes. Morphology showed that the emerged lymphocytes migrated from outside islets indicating that the disructive impact of COX-2 on beta cells is probably limited. The enhanced expression of COX-2 and insulin in random beta-cells is likely associated with the genesis of diabetes, a possible mechanism to increase or extend insulin secretion in the late period of insulitis.
It has been demonstrated that lymphocytes, particularly autoreactive T-lymphocytes mediate autoimmunity, which contributes to type 1 diabetes (TID) in humans and animals (1) . Nonobese diabetic (NOD) mouse model is a well established animal model for TID. NOD/SCID mouse lack functional T and B-cells, and show little or no immunoglobulin production due to a defective recombination of lymphocyte antigen receptor genes. The scid was transferred from C.B-I? congenic strain background of SCID (severe combined immunodeficiency) onto the diabetes susceptible NOD genetic strain (2) . Thus NOD/SCID mouse allows to accept the functional engraftment of allogenic or xenogenic cells. The injection of lymphocytes of diabetic NOD mice decisively speeds up the progression of diabetes, normally 3 weeks after the transfer. In addition, scm mice exhibit robust natural killer cell activity, which are markedly reduced in NOD/SCID mice due to the NOD background, and the macrophage population of NOD/SCm mice is functionally less mature than the ones of SCID mice, but both insulitis-and diabetes-free throughout life (3) .
Cyclooxygenase (COX) is a key enzyme in the conversion of a polyunsaturated fatty acid, arachidonic acid, to prostaglandin (PG) H 2 that is further converted into various prostanoids (4) . COX-1 is constitutively expressed in most tissues, synthesizing small physiological amounts of postaglandins. COX-2, on the other hand, is mainly expressed in activated macrophages and becomes strongly upregulated after exposure to growth factors or inflammatory stimuli, and elevated in malignant cells (5) (6) . Recent studies suggest that COX-2 rather than COX-l is predominantly expressed in the beta-cells of the islets of Langerhans, a situation opposed to most other mammalian cell types (7) . Interestingly, CDI4+ monocytes of patients with type I diabetes (TID), and of healthy subjects with diabetes-associated autoantibodies constitutively express COX-2 (8) . COX-2 gene expression in beta-cells of mouse isolated islets increases modestly with treatment of interleukin (IL)-1beta, and diminishes when the islets are exposed to dexamethasone, or cultured in the absence of IL-l beta for a few days (9) . The end products of COX-2 are powerful inhibitors of glucose-induced insulin secretion in beta-cell in vitro, but the islets ex vivo are glucose concentration dependent (10) . The effects of PGE 2 on insulin secretion are receptor mediated both in vitro and in vivo (11) . PGE 2 controls T cell receptor-dependent release of interferon (IFN)-beta from islet-reactive CD8 T cells in NOD mice, and inhibits IFN-beta release from cloned CDW and polyclonal cytotoxic T-cells via the PGE 2 receptors EP2 and EP4 (12) . The protective effect of oral insulin administration on TI D development is associated with an increased production of PGE 2 in the islets, known to be involved in the differentiation of T helper subsets, particularly promoting the Th 2 subset (13). In our previous work, we have morphologically confirmed that COX-2 is constitutively expressed in pancreatic beta-cells and goblet cells of NOD mice, and Ins-l beta-cell responded to COX-2 inhibitor in vitro (7, 14) . Here we report COX-2 and insulin were spontaneously and simultaneously expressed in beta cells of BALB/c mice, and a placebo-controlled animal testing with adoptive transferred NOD/SCID mouse supplemented by celecoxib and arachidonic acid (AA). The immunohistochemical analysis demonstrates the different molecular expressions in leukocytes of islets, and their effects on diabetogenesis in the presence or absence of a selective COX-2 inhibitor and COX-2 substrate.
MATERIALS AND METHODS

Spleen cells and adoptive transfer
Experiments were performed as approved by the Animal Ethics Committee of the University of Turku, Finland. Thirty diabetic NOD mice, age between 16-31 weeks were purchased from Denmark. The mice were dissected, the pancreas was fixed in formalin for morphological analysis, and spleens were homogenized by gentle mechanic panning in DMEM medium and loaded on 10% Ficol!. Lymphocytes were recovered from the interphase between medium and Ficol!. Trypan blue was used for assessment of cell viability before the cells were collected. Finally 5-(and-6-)-carboxyfluorescein diacetate succinimidyl ester (CFSE) was used to stain the lymphocytes. Five million lymphocytes were used in i.p. injections for each NOD/SCID mouse at age 4 week, then diet with supplements as described below.
Diet and supplements
The mice were fed with LabFor Lactamin R36 containing 4% raw fat (Stockholm, Sweden) through the experiment. The COX-2 inhibitor, celecoxib, provided by Searle, Pharmacia, USA (based on a signed agreement) was dissolved in ethanol, and then diluted to 100/-lM in PBS. Arachidonic acid (AA) was a gift from Cargill Alking Bioengineering Co. (Wuhan, China) produced from a fungus; the raw content of AA was 40%. The AA was dissolved in ethanol, and then conjugated with 1% BSA. Both celecoxib andAA was supplied in the drinking water. The dosage was calculated and added according to a rate of 10 ml per mouse per day.
Animal test
Thirty NOD/SCm mice aged 3 weeks were purchased from Bomholtgard (Ry, Denmark). The mice were divided into 6 groups (n=6) after one-week adoption. The supplement was provided for 7 days immediately after adoptive transfer. G I, placebo, fed with normal water (plus I%BSA); G2, low dose of AA (0.6g/kg/day); G3, high dose of AA (3g/kg/day); G4, low dose of celecoxib (3.3mg/kg/day); G5, high dose of celecoxib (10 mg/kg/day); The NOD/SCID mice at age 4 weeks were fed with a normal diet and supplements , and were injected 5 XlO6 total lymphocytes of diabetic NOD mice labelled with a fluorescence substance CFSE, at age of 5 weeks. The diabetic severity was determined by measuring urine glucose with glukotest stick (Roche ), the cut-off concentration of glucose was 300mg/dl. The adoptive transfer is to accelerate the development of TID; the fluorescence substance locates the transferred lymphocytes by histological analysis. Four BALB/c mice at ages of 4, 9, 17 and 32 weeks from local animal facility were used as histological control.
Antib odies, immunohistochemistry and image
For primary antibodie s rabbit anti-mouse insulin polyclonal antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and anti-human CD68 (macrophage marker) monoclonal antibody from DAKO Immunochemicals (Glostrup, Denmark) . CD3 (TCR-e) monoclonal antibody was purchased from Novocastra (Newcastle , UK). For secondary antibodies fluorescein isothiocyanate (FITC)-conjugated polyclonal swine antirabbit IgG (green) was obtained from DAKO, Alexa Fluor 568-conjugated goat anti-mouse IgG (red) and fluorescent DNA stain ToPro-3 (a monomeric thiazole orange) from Molecular Probes (Eugene, OR, USA). The animals were sacrificed just after the development of severe diabetes. The spleens and intestines for chasing grafted lymphocytes and pancreas for insulin and COX-2 expression were collected . The methods for histology and immnuohistochemistry were used as previously described (7) , except CD3 immunostaining was carried out in IOmM Tris-HCI, ImM EDTA pH 9.0 in microwave oven for 10 min for retrieval of antigen. The images were taken with Leica DM RB E confocal microscope, and recorded as TIFF files with TCS NT software, version 1.6.587 (Leica Microsystems, Heidelberg, Germany). All images were edited using Adobe PhotoShop 6.01 without adding artifacts.
RESULTS
COX-2 and insulin were co-localized in the same vesicle of pancreatic beta-cells
By high resolution of confocal microscopy, insulin ( Fig. 1 A) and COX-2 ( Fig. 1 B) were shown colocalized in the same cellular compartments ( Fig.  1 C) of beta-cells in BALB/c mice, previously known to be their expression sites in the cell. COX-2 and insulin appears tQ be always homogenously present in endoplasmic rediculum in beta-cells of islet of BALB/c mice. They are permanently intact comparing to NOD and NOD/SCID mice that can develop insulitis under autoimmunity attack.
Adoptive transferred NODISCID mice COX-2 inhibitor and the substrate
Four mice developed severe diabetes in 3 week (from the point of adoptive transfer and with supplemental diet, placebo, G I); subsequently similar diabetogenesis is listed in Table 1 . The prevention was not striking whether in the possible prostaglandin increased groups (G2 and G3) or decreased groups (G4 and G5). However, apparently week after the adoptive transfer; 2B, CD68 specifically expressed in macrophages of inflamed islets (arrow)in NOD/SClD mouse; 2C, COX-2 and insulin in islet, the ToPr03 is f or nuclear staining. Emerged lymphocytes indicated by grey annw, and stronger stained beta-cells by COX-2 and insulin indicated by white arrow (NOD mouse at 17 week) ; 2D, a blood vessel with lymphocytes flo w was indicated by white anvw (NOD/SClD mouse at age of 10 week); 2E, COX-2 and insulin stained islet, the macrophages flow into islet from a blood vessel indicated by white arrow (NOD mouse at age of 17 week); 2F, insulin and COX-2 expression indicate beta-cell destruction from middle area of islet, apparently from the port of blood vessel (white arrow, NOD mouse at age of 17 week); 2G, CD68 stained macrophages (arrow) 
in mesenteric tissues between islets and intestine (NOD/SCID mouse at age of9 week); 2H, CD3 stained lymphoctes (white GlTOW) in spleen (NOD/SCID at age of9 week); 21, CD3 stained lymphocytes (white arrow) in islet indicate that activated T-cells in inflamed islet (NOD/SCID mouse). The bar length is 10f.1M
COX-2 inhibition led to a delay of diabetogenesis in more than 50% of NOD/SCm mice (G3) of the 3rd week, comparing with high dose AA (G4). The COX-2 inhibition at high dosage may prevent diabetes better than low dosage in this animal model. These data indicate that elevated COX-2 in the early stages may participate in the T10 development even though many other unknown factors may be involved.
Adoptive transfer oflymphocytes in intestine
After adoptive transfer of insulitis from diabetic NOD mice by lymphocytes, some of them accumulated or homed in the intestine and pancreas of recipients NOD/SCm mice. These cells express classical antigen-presenting molecules and are costimulators of adhesion molecules in T-cell activation, such as 1CAM-I and LAF-l. The CFSEstained lymphocytes in vivo normally are visible within I week since cellular division dilutes the dye. It has been reported that lymphoc yte selectively move to the islets via the intestine . In this animal model CFSE-stained lymphocytes were visible after injection 3 to 4 weeks ( Fig. 2A, indicated by arrow) , but not seen in 5 weeks, which indicates lymphocytes mediated adoptive transfer was successful.
COX-2 expressed in macrophages, but not in lymphocytes
The lymphocytes play major role in trigger of diabetes. It has been reported that COX-2 can be elevated in activated lymphocytes (15) . The macrophages were separately stained with CD68 in islets (Fig. 2B) . Large amount of macrophages were also COX-2 positive in mesenteric tissues (Fig. 2G ) that is a path for homing of lymphocytes. The lymphocytes were stained positive with CD3 in spleen ( Fig. 2H ) and in inflamed islet (Fig. 21) . The lymphocytes emerged in inflamed pancreas was from blood vessels ( Fig. 20 and E) , and the destruction of beta-cells seemingly began from where the islet was connected with the blood vessel , it can even start from the middle islet (Fig. 2F) . By observing samples from all animals we found that COX-2 was not expressed in activated lymphocytes that emerged into inflamed islets. There was no emerged lymphocytes inside undestroyed beta-cell zone, which indicates they were remotely originated.
COX-2 and insulin in beta-cells
Insulitis is characterized as beta-cell in the process of irreversible destruction by autoimmunity attack, the diabetes only occurs when more than 96% of beta-cells are destroyed. Insulin and COX-2 in islets were overlaid in existed live beta-cells. Some of the beta-cells are much stronger and intensely stained for insulin and COX-2 in the inflamed islets in most NOD, or NOD/SCID mice (Fig. 2C, indicated by arrow) . The random special beta-cells apparently indicate a mechanism to remain efficient in insulin secretion when most beta-cells are destroyed. It is clearly visible that the emerged lymphocytes were exuberated in islets by adoptive transfer. They aggressively approached the rest of undestroyed beta-cells in the islet (Fig. 2C , indicated by arrow).
DISCUSSION
Lymphocytic infiltration of the pancreatic islets is an approach to study insulitis, a condition occurring after the onset of type 1 diabetes. COX-2 and insulin virtually indicate the destruction of betacells during the progression of insulitis. Our morphological data show that COX-2 and insulin are simultaneously present in beta-cells in intact islets of BALB/c mice, or until destruction in inflamed islets. They were strongly expressed in parallel in the betacells, and co-localized in the same vesicles of the endoplasmic reticulum. Insulin and COX-2 genes have different regulatory mechanisms, but with shared mitogen-activated protein (MAP) kinases signaling pathways (16) (17) .
Celecoxib, a selective COX-2 inhibitor, demonstrated to inhibit COX-2 dependent PGE 2 production and markedly increase insulin secretion from cultured INS-IE cells (7) . This suggests insulin secretion is associated with COX-2 expression in vivo as well. However, the regulatory network for insulin secretion is a complex. At present the relative correlation of COX-2, iNOS and their products, different cytokines and other factors for insulin secretion remain speculative both during normal physiological conditions, as well as during progression of insulitis toward clinical diabetes. Double immunostaining and confocal microscopy distinguish the expression of COX-2 in beta-cells and infiltrating leukocytes in insulitis. Positive COX-2 expression in beta-cells and the macrophages in the inflamed islets and mesenteric tissues were detected, but not in emerged lymphocytic zones or inside peri-islets in tested mice. Both T-lymphocytes and macrophages can be easily activated in vitro by COX-2 inducers, phorbol The diabetogenesis in different groups was adjusted to in weeks. The testing procedure was described in methods and materials.
myristate acetate (PMA), or lipopolysaccharide. The difference of COX-2 activation in vitro and in vivo may indicate a different signalling pathway, or different threshold level. Particularly, independent regulation of antigen presenting cells (APC), such as macrophages and dendritic cells have been regarded as promoters of T cell activation in situ during the development of islet inflammation. Thus, COX-2 positive macrophages may actually fail to activate the T cells because of anergy, in which the lymphocyte is not activated following an antigen encounter. This may contribute to the functionally unmatural macrophages in NOD/SCID regardless of COX-2 positive or negative expression. This is consistent with the suggestion that T lymphocytes are activated by B-lymphocyte as APC in autoimmune processes (17) . This anergy has been regarded as one of the possibilities for the prevention of autoimmunity in individuals with high genetic susceptibility. Ifthis is the case, COX-2 may also have a tendency to prevent TID by rendering cells unresponsive to antigens, which is probably similar to oral tolerance (18) . The role of macrophages in the inflamed islets is not restricted to secretion of cytotoxic and inflammation-inducing mediators; they also produce substances that participate in tissue reorganization including enzymes such as hyaluronidase, elastase, and collagenase, anti-proteases, regulatory growth factors and others. Macrophage scavenger receptors have been implicated in the pathologic deposition (19) , these COX-2 positive macrophages that always appeared in inflamed islets are there perhaps to remove cellular debris of beta-cells through phagocytosis (20) . In our observation it emerged that CD3 positive T cell clones in islets were probably activated remotely through B-lymphocyte APC. The activation factors are possibly cytokines rather than COX-2 downstream products. The lymphocytes in inflamed islets are possibly initially exuberated by intrinsically unknown factors and autoantibodies IAA, ICA and GAD (21) . These autoantibodies influenced lymphocytes were brought in by adoptive transfer, which essentially triggers irreversible insulitis. The xenografted lymphocytes speeds up diabetes directly, which may also affect the COX-2 inhibitor animal test because drug had relatively limited time on cellular action. However, negative COX-2 expression in activated lymphocytes, which indicates COX-2 does not play a direct role in diabetogenesis. This may explain that COX-2 inhibition did not efficiently prevent or delay the diabetogenesis, which was shown in STZ BB rats (22) .
From the randomly high expression of COX-2 and insulin, which has never been seen in NOD mice, we can reasonably suggest that there is a possible structural mechanism which increases the insulin expression associated with enhanced COX-2 expression in beta-cells, if necessary. Those betacells may increase the rate of insulin secretion, which may correspond to the human honeymoon period in TID. However, these are complex and controversial in vivo and ex vivo data. Recent reports show that celecoxib does not prevent the dysfunction of beta-cell or islet degeneration in isolated rat and human islets caused by cytokines (23) . In conclusion, effective protection of diabetes from beta-cell destruction may therefore require inhibition of multiple effector mechanisms. The regulation of insulin secretion and possible correlation with COX-2 in vivo exists, but needs to be studied further.
